ECG Biomarker Development Market

Electrophysiological biomarkers lead the biomarker type with 40.7% share in 2026, while cardiovascular disease detection accounts for 36.0% of application share and pharmaceutical companies represent 40.1% of end-user share. Demand reflects repeatable ECG analysis, routine detection pathways, drug-safety monitoring, consistent signal definitions, and cross-site comparability.